Glenmark Pharmaceuticals’ subsidiary Glenmark Pharmaceuticals S.A. (GPSA) has completed the Phase 1 supporting studies and the submission of a clinical trial application to the Paul-Ehrlich Institute in Germany with a novel clinical development candidate, GBR 1302. GBR 1302 is a HER2xCD3 bi-specific antibody based on the company’s proprietary BEATTM platform. GBR 1302 is the first clinical development candidate based on the BEATTM technology. The company expects to obtain approval for the initiation of clinical studies with GBR1302 during this financial year.
GBR 1302 material for Phase 1 clinical trials was manufactured in the company’s GMP production unit in Switzerland. HER2, also known as HER2/neu, or receptor tyrosine-protein kinase erbB-2, is the target of the multibillion dollar antibody cancer drugs trastuzumab, pertuzumab and trastuzumab emtansine and is implicated in breast cancer, ovarian, gastric, and certain uterine cancers.
Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical company and ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |